PAION AG: Management Board Change
26-Apr-2011
- Germany
The biopharmaceutical company PAION AG announced that Dr Gavin Kilpatrick has stepped down from his position as a member of the Management Board and will be leaving the company on 30 April 2011. In his role as Chief Scientific Officer, Dr Kilpatrick was responsible for production, pre-clinical development, drug discovery, project management and intellectual property. Dr Wolfgang Söhngen, PAION’s CEO, and Dr Mariola Söhngen, PAION’s CMO, will take over these responsibilities in the future.
Other news from the department people
